F-group (family)
206.1.1.72 Pkinase, Pkinase_fungal
Ligands and drugs
655
Member domains
256
with ligand contacts (≤ 4 Å)
39.1% of members
241
with DrugDomain annotations
36.8% of members
152
with a DrugBank compound
23.2% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 206.1.1.72 belongs to X-group 206 Protein kinase/SAICAR synthase/ATP-grasp, which binds 10.2 ligand superclasses per 20 proteins, broader than 96% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB16833 | ADP | Adenosine disphosphate | 13 |
| DB12010 | — | Fostamatinib | 7 |
| DB00131 | AMP | Adenosine phosphate | 6 |
| DB04604 | 5ID | 5-iodotubercidin | 4 |
| DB09459 | TLA | L-tartaric acid | 4 |
| DB14756 | SRT | meso-Tartaric acid | 3 |
| DB00244 | — | — | 2 |
| DB00640 | ADN | Adenosine | 2 |
| DB02152 | KSA | K-252a | 2 |
| DB02175 | MLA | Malonic acid | 2 |
| DB03693 | CKI | N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide | 2 |
| DB03909 | ACP | Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate | 2 |
| DB04349 | PGO | (S)-propane-1,2-diol | 2 |
| DB04703 | H1N | Hesperidin | 2 |
| DB06151 | — | Acetylcysteine | 2 |
| DB07789 | FRS | 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea | 2 |
| DB08052 | KS1 | PP-121 | 2 |
| DB08059 | KWT | Wortmannin | 2 |
| DB00233 | — | Aminosalicylic acid | 1 |
| DB00945 | — | Acetylsalicylic acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 17 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 13 |
| 5TL | 2-azanyl-5-phenyl-3-(4-sulfamoylphenyl)benzamide | 12 |
| MGmetal | MAGNESIUM ION | 12 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 8 |
| NAmetal | SODIUM ION | 8 |
| ZNmetal | ZINC ION | 7 |
| 0CK | 4-[1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine | 6 |
| AMP | ADENOSINE MONOPHOSPHATE | 6 |
| D5Q | 4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide | 6 |
| 16W | 3-[(3-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | 4 |
| 1QG | (3S)-3-{4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridin-2-yl}morpholine | 4 |
| 1QM | 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine | 4 |
| 4OQ | 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin-1-yl)-dibenzodiazepine | 4 |
| 4OR | (S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide | 4 |
| 5ID | (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL | 4 |
| 9WG | 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-6-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one | 4 |
| 9XK | ~{N}-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxidanylidene-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]ethanamide | 4 |
| A1JCP | (2~{Z})-2-cyano-2-[3-ethyl-5-[(~{E})-[2-[methyl-(1-methylpiperidin-4-yl)amino]pyridin-4-yl]iminomethyl]-4-oxidanylidene-1,3-thiazol-2-ylidene]-~{N}-[2,2,2-tris(fluoranyl)ethyl]ethanamide | 4 |
| DXV | 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid | 4 |